CHEBI:72312 - pasireotide

Main ChEBI Ontology Automatic Xrefs Reactions Pathways Models
ChEBI Name pasireotide
ChEBI ID CHEBI:72312
Definition A six-membered homodetic cyclic peptide composed from L-phenylglycyl, D-tryptophyl, L-lysyl, O-benzyl-L-tyrosyl, L-phenylalanyl and modified L-hydroxyproline residues joined in sequence. A somatostatin analogue with pharmacologic properties mimicking those of the natural hormone somatostatin; used (as its diaspartate salt) for treatment of Cushing's disease.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
Download Molfile XML SDF
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula C58H66N10O9
Net Charge 0
Average Mass 1047.20620
Monoisotopic Mass 1046.50142
InChI InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1
InChIKey VMZMNAABQBOLAK-DBILLSOUSA-N
SMILES NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@H](CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O)OC(=O)NCCN)c1ccccc1
Roles Classification
Chemical Role(s): Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
Biological Role(s): hormone
Originally referring to an endogenous compound that is formed in specialized organ or group of cells and carried to another organ or group of cells, in the same organism, upon which it has a specific regulatory function, the term is now commonly used to include non-endogenous, semi-synthetic and fully synthetic analogues of such compounds.
(via peptide hormone )
Application(s): antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
View more via ChEBI Ontology
ChEBI Ontology
Outgoing pasireotide (CHEBI:72312) has role antineoplastic agent (CHEBI:35610)
pasireotide (CHEBI:72312) is a homodetic cyclic peptide (CHEBI:24613)
pasireotide (CHEBI:72312) is a peptide hormone (CHEBI:25905)
pasireotide (CHEBI:72312) is conjugate base of pasireotide(2+) (CHEBI:72315)
Incoming pasireotide(2+) (CHEBI:72315) is conjugate acid of pasireotide (CHEBI:72312)
IUPAC Name
cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-benzyl-L-tyrosyl-L-phenylalanyl-(4R)-4-{[(2-aminoethyl)carbamoyl]oxy}-L-prolyl]
INNs Sources
pasireotida WHO MedNet
pasiréotide WHO MedNet
pasireotide WHO MedNet
pasireotidum WHO MedNet
Synonyms Sources
cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-) ChemIDplus
SOM 230 ChemIDplus
SOM-230 ChemIDplus
SOM230 ChemIDplus
Manual Xrefs Databases
D10147 KEGG DRUG
Pasireotide Wikipedia
View more database links
Registry Numbers Types Sources
396091-73-9 CAS Registry Number ChemIDplus
396091-73-9 CAS Registry Number KEGG DRUG
9469122 Reaxys Registry Number Reaxys
Citations Waiting for Citations Types Sources
20643121 PubMed citation Europe PMC
20970474 PubMed citation Europe PMC
21264796 PubMed citation Europe PMC
21330405 PubMed citation Europe PMC
21493671 PubMed citation Europe PMC
21506098 PubMed citation Europe PMC
21525729 PubMed citation Europe PMC
21532334 PubMed citation Europe PMC
21673137 PubMed citation Europe PMC
21732759 PubMed citation Europe PMC
22170729 PubMed citation Europe PMC
22282526 PubMed citation Europe PMC
22383336 PubMed citation Europe PMC
22573933 PubMed citation Europe PMC
22634958 PubMed citation Europe PMC
22713526 PubMed citation Europe PMC
22736724 PubMed citation Europe PMC
22745760 PubMed citation Europe PMC
22807497 PubMed citation Europe PMC
22960304 PubMed citation Europe PMC
22965070 PubMed citation Europe PMC
23102680 PubMed citation Europe PMC
23137853 PubMed citation Europe PMC
23345100 PubMed citation Europe PMC
Last Modified
22 February 2017